676 related articles for article (PubMed ID: 1330165)
21. Evaluation of SQ 28,603, an inhibitor of neutral endopeptidase, in conscious monkeys.
Seymour AA; Abboa-Offei B; Asaad MM; Rogers WL
Can J Physiol Pharmacol; 1991 Oct; 69(10):1609-17. PubMed ID: 1663819
[TBL] [Abstract][Full Text] [Related]
22. Renal response of anesthetized rats to low-dose infusion of atrial natriuretic peptide.
Soejima H; Grekin RJ; Briggs JP; Schnermann J
Am J Physiol; 1988 Sep; 255(3 Pt 2):R449-55. PubMed ID: 2970807
[TBL] [Abstract][Full Text] [Related]
23. Is atrial natriuretic peptide-guanosine 3',5' cyclic monophosphate coupling a determinant of urinary sodium excretion in essential hypertension?
Sagnella GA; Singer DR; Markandu ND; Buckley MG; MacGregor GA
J Hypertens; 1992 Apr; 10(4):349-54. PubMed ID: 1316400
[TBL] [Abstract][Full Text] [Related]
24. Role of endogenous atrial natriuretic peptide in chronic anemia in the ovine fetus: effects of a non-peptide antagonist for atrial natriuretic peptide receptor.
Silberbach M; Woods LL; Hohimer AR; Shiota T; Matsuda Y; Davis LE
Pediatr Res; 1995 Nov; 38(5):722-8. PubMed ID: 8552440
[TBL] [Abstract][Full Text] [Related]
25. Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.
Rousso P; Buclin T; Nussberger J; Décosterd LA; La Roche SD; Brunner-Ferber F; Brunner HR; Biollaz J
J Hypertens; 1999 Mar; 17(3):427-37. PubMed ID: 10100082
[TBL] [Abstract][Full Text] [Related]
26. The dopamine receptor antagonist haloperidol blocks natriuretic but not hypotensive effects of the atrial natriuretic factor.
Hansell P; Fasching A; Sjöquist M; Andén NE; Ulfendahl HR
Acta Physiol Scand; 1987 Jul; 130(3):401-7. PubMed ID: 2957892
[TBL] [Abstract][Full Text] [Related]
27. Renal effects of concurrent E-24.11 and ACE inhibition in the aorto-venocaval fistula rat.
Kirk JE; Wilkins MR
Br J Pharmacol; 1996 Nov; 119(5):943-8. PubMed ID: 8922744
[TBL] [Abstract][Full Text] [Related]
28. Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure.
Rademaker MT; Charles CJ; Kosoglou T; Protter AA; Espiner EA; Nicholls MG; Richards AM
Am J Physiol; 1997 Nov; 273(5):H2372-9. PubMed ID: 9374774
[TBL] [Abstract][Full Text] [Related]
29. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin.
Lisy O; Jougasaki M; Schirger JA; Chen HH; Barclay PT; Burnett JC
Am J Physiol; 1998 Sep; 275(3):F410-4. PubMed ID: 9729514
[TBL] [Abstract][Full Text] [Related]
30. Renal and hormonal effects and tolerance of an ANP analogue in healthy man.
Eiskjaer H; Schmiegelow M; Jespersen B; Tietze IN; Jensen JD; Sørensen SS; Thomsen K; Pedersen EB
Eur J Clin Pharmacol; 1991; 41(6):547-54. PubMed ID: 1840038
[TBL] [Abstract][Full Text] [Related]
31. Basal and volume expansion-stimulated plasma atrial natriuretic peptide concentrations and hemodynamics in conscious rats: effects of SCH 39.370, an endopeptidase inhibitor, and C-ANF-(4-23), a clearance receptor ligand.
Kukkonen P; Vuolteenaho O; Ruskoaho H
Endocrinology; 1992 Feb; 130(2):755-65. PubMed ID: 1531129
[TBL] [Abstract][Full Text] [Related]
32. The pharmacokinetics of 125I-atrial natriuretic factor in anaesthetized rats. Effects of neutral endopeptidase inhibition with candoxatrilat and of ANF-C receptor blockade.
Barclay PL; Bennett JA; Greengrass PM; Griffin A; Samuels GM; Shepperson NB
Biochem Pharmacol; 1992 Sep; 44(6):1013-22. PubMed ID: 1417928
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of kidney neutral endopeptidase (EC 3.4.24.11) and renal function in experimental cirrhosis.
Sansoè G; Aragno M; Mastrocola R; Cutrin JC; Silvano S; Mengozzi G; Smedile A; Rosina F; Danni O; Rizzetto M
Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1337-43. PubMed ID: 16449355
[TBL] [Abstract][Full Text] [Related]
34. Reduced natriuretic effect of atrial natriuretic peptide in nephrotic syndrome: a possible role of decreased cyclic guanosine monophosphate.
Jespersen B; Eiskjaer H; Mogensen CE; Sørensen SS; Pedersen EB
Nephron; 1995; 71(1):44-53. PubMed ID: 8538848
[TBL] [Abstract][Full Text] [Related]
35. Enkephalinase inhibition increases plasma atrial natriuretic peptide levels, glomerular filtration rate, and urinary sodium excretion in rats with reduced renal mass.
Lafferty HM; Gunning M; Silva P; Zimmerman MB; Brenner BM; Anderson S
Circ Res; 1989 Sep; 65(3):640-6. PubMed ID: 2548762
[TBL] [Abstract][Full Text] [Related]
36. Interaction of ANP and bradykinin during endopeptidase 24.11 inhibition: renal effects.
Smits GJ; McGraw DE; Trapani AJ
Am J Physiol; 1990 May; 258(5 Pt 2):F1417-24. PubMed ID: 2140018
[TBL] [Abstract][Full Text] [Related]
37. Renal and vascular effects of C-type and atrial natriuretic peptides in humans.
Pham I; Sediame S; Maistre G; Roudot-Thoraval F; Chabrier PE; Carayon A; Adnot S
Am J Physiol; 1997 Oct; 273(4):R1457-64. PubMed ID: 9362312
[TBL] [Abstract][Full Text] [Related]
38. Potentiation of natriuretic peptides by neutral endopeptidase inhibitors.
Seymour AA; Abboa-Offei BE; Smith PL; Mathers PD; Asaad MM; Rogers WL
Clin Exp Pharmacol Physiol; 1995 Jan; 22(1):63-9. PubMed ID: 7768036
[TBL] [Abstract][Full Text] [Related]
39. Renal effects of atrial natriuretic peptide during dopamine infusion.
Hirata Y; Fukui K; Hayakawa H; Suzuki E; Sugimoto T; Kimura K; Matsuoka H; Sugimoto T
Am J Hypertens; 1990 Nov; 3(11):866-9. PubMed ID: 2175625
[TBL] [Abstract][Full Text] [Related]
40. Renal and systemic effects of urodilatin in rats with high-output heart failure.
Abassi ZA; Powell JR; Golomb E; Keiser HR
Am J Physiol; 1992 Apr; 262(4 Pt 2):F615-21. PubMed ID: 1533100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
